HOLON, Israel, Oct. 3, 2023
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced, it will
present innovative single-cell approaches and high resolution
single cell spatial transcriptomics data at the Single Cell
Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.
The data will highlight the computational characterization of
PVRIG's expression providing a deeper understanding of its unique
biology and rationale for targeting PVRIG in tumors, typically
those not responding to immunotherapy.
Poster presentation details:
Poster Title: Elucidating the Mechanism of Action of the
Novel Immune Checkpoint PVRIG: Insights from Single-Cell and
High-Resolution Spatial Transcriptomics
Poster number: P1.65
Presenter: Roy Granit, Ph.D., Head of Computational
Discovery, Compugen Ltd.
Date: Monday, October 9,
2023
The poster will be available on the publications section of
Compugen's website, www.cgen.com, following presentation.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is in IND enabling studies. COM503 is a
potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-at-single-cell-genomics-2023-meeting-301945523.html
SOURCE Compugen Ltd.